Core Viewpoint - The company Yiming Anke has decided to terminate its licensing agreement with Axion for two drug candidates, IMM2510 and IMM27M, and will reclaim all rights previously granted to Axion, including global development and commercialization rights outside Greater China [1] Group 1: Licensing Agreement Details - The initial licensing agreement with Axion began in August 2024, with a collaboration amount exceeding $2 billion [1] - Yiming Anke has received a total of $35 million in upfront and milestone payments from Axion prior to the termination of the agreement [1] Group 2: Reasons for Termination - The CEO of Yiming Anke stated that the collaboration with Axion had been pleasant, but the slow clinical progress due to funding constraints led to the decision to reclaim the rights [1] - Shareholders had been advising the company to reclaim the overseas rights for the two products, making this an opportune moment for the company [1] Group 3: Product Information - IMM2510 is a PD-L1/VEGF bispecific antibody, which is a significant target in tumor immunotherapy, and its potential to disrupt the PD-1 market is highly anticipated [2] - The market for PD-1/VEGF bispecific antibodies has seen increased activity since 2024, with notable deals such as the $1.25 billion upfront payment received by a competitor for a similar product [2] Group 4: Future Plans - Yiming Anke expressed confidence in the therapeutic potential of IMM2510 and IMM27M and aims to accelerate their clinical development [3] - The company plans to seek new business development partnerships with large multinational pharmaceutical companies, which will be simplified by reclaiming the rights from Axion [3]

Group 1 - The core viewpoint of the article highlights the strong performance of Hong Kong innovative drug stocks, particularly WuXi AppTec (2268.HK), which rose by 5.5% to HKD 68.75, marking its fourth consecutive day of increase [1] - Other notable performers include Sangamo Therapeutics, which increased by over 7%, WuXi Biologics rising by over 6%, Innovent Biologics up nearly 6%, and WuXi AppTec gaining nearly 5%, all achieving four consecutive days of growth [1] - According to a report by CMB International published in December, the trend of innovative drugs going overseas is expected to continue into 2026, with a focus on the clinical progress and data validation of pipelines that have already entered international markets [1] Group 2 - The article mentions that the recently enacted U.S. Biosecurity Act is not expected to significantly impact the operations of Chinese CXO companies, as it does not affect Medicaid and Medicare procurement and has clear definitions regarding related parties [1] - CMB International's industry outlook suggests a more conservative investment approach, emphasizing opportunities in undervalued stocks, and recommends buying Sangamo Therapeutics, Genscript Biotech, WuXi AppTec, and China National Pharmaceutical Group [1]

Group 1 - The core viewpoint of the article highlights a significant rally in Hong Kong's innovative drug concept stocks, with notable increases in companies such as WuXi AppTec (2268.HK), which rose by 5.5% to HKD 68.75, marking its fourth consecutive day of gains [1] - Other companies in the sector also experienced substantial increases, including 3SBio, which rose over 7%, WuXi Biologics, which increased over 6%, Innovent Biologics, which gained nearly 6%, and WuXi AppTec, which saw a nearly 5% rise, all achieving their fourth consecutive day of growth [1] - According to a report by CMB International published in December, the trend of innovative drugs going overseas is expected to continue in the long term, with a focus on the clinical progress and data validation of pipelines that have already gone abroad as a key catalyst [1] Group 2 - On the policy front, the U.S. Biodefense Act has been signed into law; however, its impact on Chinese CXO companies is expected to be limited due to its non-coverage of Medicaid and Medicare procurement and clear definitions of related parties, as well as the relatively small proportion of revenue from U.S. administrative agencies for Chinese CXOs [1] - The industry outlook from CMB International indicates a more conservative investment approach, focusing on undervalued stock opportunities, with recommendations to buy 3SBio, Genscript Biotech, WuXi AppTec, and China National Pharmaceutical Group [1]

Group 1 - The A-share market experienced narrow fluctuations on January 7, with coal, chips, and innovative drug sectors leading in gains. The Southern Innovative Drug ETF (159858.SZ) rose by 1.60%, and Baijie Shenzhou increased by 3.29% [1] - The Chinese innovative drug industry is expected to undergo a value return and structural reshaping by 2025, with a shift in core logic towards product strength, platform capability, and global operational ability [1] - Policies are transitioning from encouraging innovation to a new phase of systematic and precise guidance, providing institutional support for original innovation [1] Group 2 - Capital is concentrating on companies with core technology platforms, clear clinical value, and global potential, favoring mid-to-late-stage projects in areas such as ADC, bispecific antibodies, CGT, and AI drug development [1] - The transaction amount for innovative drugs going overseas has reached a historical high, with deepening collaboration models [1] - Domestic ADC and bispecific antibody products have been approved and show globally leading data, while breakthroughs have been made in small molecule drugs targeting "undruggable" targets, and significant progress has been observed in cell therapies and nucleic acid drugs [1] Group 3 - The industry is transitioning from following innovation to original innovation, and from technology input to systematic output [1] - The trend for the innovative drug industry is positive, with strengthened global competitiveness, ongoing international expansion, and gradual realization of commercial profitability [1] - The medical device industry is experiencing a calming of influencing factors, with accelerated innovation and internationalization [1] Group 4 - The innovative drug industry is showing enhanced innovation vitality and significant internationalization results, with sufficient long-term development momentum [1] - The Southern Innovative Drug ETF (159858.SZ) can focus on innovative drugs and the industry chain, sharing the growth dividends of truly competitive companies amid industry differentiation and seizing opportunities for value reshaping [1]

1月7日，科创创新药ETF国泰（589720）涨超3.6%，创新与出海主线获市场关注。 科创创新药ETF国泰（589720）聚焦科创板创新药企业，跟踪汇聚30家代表性优质公司的上证科创板创 新药指数，以高成长biotech为主，产品20%涨跌幅限制使其更贴合板块波动。从业绩表现来看，2024年 9月24日至2025年10月31日市场反弹期间，科创新药/恒生港股通创新药指数涨幅分别为 143.70%/135.34%，科创新药指数或有助于在市场风险偏好回升时更好地分享科创板的弹性。 （文章来源：每日经济新闻） 中泰证券指出，2025年医药板块迎来强势反弹，行情由AI+和创新药推动，反映出中国创新能力的质的 飞跃及出海逻辑兑现。化学制药等细分行业经历政策改革后呈现复苏。创新药出海从"叙事"进入兑现阶 段，交易金额创新高，国内政策全链条支持创新药，首次增设商保目录打开支付空间。CRO/CDMO行 业内外需共振，全球投融资恢复带动订单增长，供给端逐步出清，板块有望迎来"戴维斯双击"。2026年 医药板块投资思路将延续创新成长+困境反转逻辑，建议关注创新药及产业链、需求复苏及经营拐点等 方向。 ...

Core Insights - The innovative drug ETF Tianhong (517380) has seen significant trading activity, with a transaction volume of 28.36 million yuan, and the underlying index, the Hang Seng Shanghai Shenzhen Hong Kong Innovative Drug Select 50 Index (HSSSHID), has risen nearly 3%, marking a strong performance with several constituent stocks like Kelaiying (06821) and Yifang Bio (688382) showing notable gains [1] Product Highlights - The innovative drug ETF Tianhong (517380) spans the markets of Shanghai, Hong Kong, and Shenzhen, selecting 50 leading innovative drug companies, with 40% from Hong Kong and 60% from A-shares, covering key areas such as biopharmaceuticals and chemical pharmaceuticals [1] Relevant Events - The new national medical insurance directory and the first commercial insurance innovative drug directory were implemented on January 1, 2026, adding 50 types of first-class innovative drugs and 19 types of commercial insurance drugs, establishing a "medical insurance + commercial insurance" payment loop. In 2025, China approved 76 innovative drugs, a significant increase of 58.3% from 48 in 2024, with over 80% being domestically produced, laying a foundation for sales growth in 2026 [1] Industry Trends - China's innovative drug licensing abroad has seen a breakthrough, with total transaction amounts reaching 135.655 billion USD by December 31, 2025, including upfront payments of 7 billion USD and 157 transactions, significantly surpassing the 51.9 billion USD and 94 transactions recorded in 2024 [2] - According to Zhongtai Securities, the pharmaceutical market is expected to continue benefiting from innovation-driven growth and industrial upgrades, with investment strategies for 2026 focusing on innovative drugs and their supply chains, demand recovery, and AI-related opportunities [2] Market Dynamics - The current innovative drug market differs from the 2019-2021 period, as the focus has shifted from narrative to actual execution, with transaction amounts reaching new highs, reflecting a transition in China's innovative capabilities from quantity to quality. Continuous policy support for innovative drugs, including the introduction of a commercial insurance directory, is expected to enhance payment options [3] - Companies with mature products successfully entering multinational corporations (MNCs) and those with strong platform advantages in cutting-edge technologies (such as ADC, small nucleic acids, and bispecific antibodies) are recommended for attention, along with potential collaboration opportunities [3]

2026年1月7日，恒生医药ETF（159892）上涨2.94%，冲击三连阳。持仓股康方生物、和黄医药、翰森 制药涨超4%。 中信建投证券认为，国内上市药企正迎来创新收获期，呈现自主研发+海外BD双轮驱动格局。整体看， 中国药企从单一市场驱动转向全球价值创造，JPM大会将成为展示临床数据、洽谈海外合作的核心舞 台。 恒生医药ETF（159892）聚焦创新药、CXO及相关产业，港交所18A制度优势下覆盖众多创新标的（百 济神州、信达生物等），在创新药出海+商保目录等催化下有望延续估值修复行情。 消息面上，近日，国家药监局官方微信公号发文称，2025年我国已批准上市的创新药达76个，大幅超过 2024年全年48个，创历史新高。此外，2025年我国创新药对外授权交易总金额超过1300亿美元，授权交 易数量超过150笔，同样创历史新高。 ...

Group 1: Market Performance - Hong Kong's innovative drug ETF (159570) surged by 3%, with a trading volume exceeding 1.5 billion yuan, following a net inflow of over 62 million yuan today after a previous inflow of 430 million yuan [1][3] - As of January 6, the latest scale of the Hong Kong innovative drug ETF reached over 23.3 billion yuan, leading its peers in the same category [1] Group 2: Economic Signals - Federal Reserve Governor Milan indicated that upcoming economic data may support further interest rate cuts, with expectations of a reduction exceeding 100 basis points this year [3] - Wall Street analysts suggest that if the U.S. unemployment rate rises to 4.7% by December 2025, the Fed may cut rates by 25 basis points this month [3] Group 3: Company Developments - Brain-computer interface "unicorn" Strong Brain Technology completed a financing round of 2 billion yuan, second only to Musk's Neuralink [3] - AI pharmaceutical company Insilico Medicine announced a long-term collaboration with Siveya for anti-tumor drug development, with a total deal value of 888 million USD [3] Group 4: New Drug Approvals - On January 6, BeiGene announced that its self-developed BCL2 inhibitor, Baiyueda® (sotucumab), received conditional approval from the National Medical Products Administration [3] - Shiyao's SYS6017 has initiated Phase II clinical trials for the prevention of shingles [3] Group 5: Investment Insights - Zhongtai Securities predicts that the pharmaceutical sector's opportunities in 2025 will focus on innovation and industry upgrades, with investment strategies continuing into 2026 [5] - The report emphasizes the importance of "innovative drugs and industry chains, demand recovery, and AI" as key investment dimensions [5] Group 6: J.P. Morgan Healthcare Conference - The 44th J.P. Morgan Healthcare Conference is set to take place from January 12 to 15, 2026, in San Francisco, attracting over 8,000 global participants [6] - The conference will feature over 500 listed companies and thousands of startups, focusing on "capital + strategy" discussions [6] Group 7: Industry Trends - Three major trends are highlighted for 2026: the continued rise of gene and cell therapies, deep integration of AI in pharmaceuticals, and the emergence of new market forces [7] - The report notes that over 20 gene editing companies will showcase breakthroughs in CAR-T and base editing at the conference [7] Group 8: MNC Engagement - Multinational corporations (MNCs) are willing to pay higher prices for innovative drugs from China, with the average total package for drugs purchased from China being 2.76 billion USD, compared to 1.29 billion USD for those from overseas [8] - The willingness of MNCs to pay a premium for Chinese innovations is driven by the need to fill significant pipeline gaps due to impending patent expirations [8] Group 9: Investment Focus - Investment strategies should focus on companies with strong clinical development capabilities and those in popular therapeutic areas such as ADCs, GLP-1, and dual antibodies [11] - Companies that can produce high-quality late-stage clinical assets are likely to attract MNC interest [11] Group 10: Key Therapeutic Areas - The report identifies key therapeutic areas for investment, including ADCs, GLP-1, dual antibodies, and neuroscience, emphasizing the need for innovative platforms and clinical data superiority [12]

Group 1 - The Chinese innovative pharmaceutical industry has transitioned from "R&D accumulation" to "value validation," with significant acceleration expected by 2025, as evidenced by record-breaking figures in overseas licensing transactions and new drug approvals [1][4] - In 2025, the total amount of overseas licensing transactions for Chinese innovative drugs reached $135.655 billion, with 157 deals, significantly surpassing the previous year's figures of $51.9 billion and 94 deals, indicating strong international recognition of China's innovative drug value [5][17] - A total of 76 innovative drugs were approved for market entry in China in 2025, including 47 chemical drugs, 23 biological products, and 6 traditional Chinese medicines, marking a historic high and showcasing China's growing strength in the global biopharmaceutical innovation sector [5][17] Group 2 - The innovative drug sector performed well in the capital markets in 2025, with the Hong Kong innovative drug index rising by 66.52%, outperforming the Hang Seng Index's 27.77% increase, while the A-share CS innovative drug index rose by 19.34%, exceeding the CSI 300 Index's 17.66% [6][18] - The current market trend is characterized as a systematic re-evaluation of the value of Chinese innovative drugs, driven by three synergistic factors: improved policy efficiency, optimized capital ecology, and leading global R&D scale [10][22] - Policies have been established to support the entire lifecycle of innovative drugs, including measures for accelerated review and multi-tiered payment systems, enhancing the efficiency of drug approval processes [10][21][22] Group 3 - The capital ecosystem for innovative drugs has been optimized, with government-led funds and market-driven investments providing continuous financial support for the entire lifecycle of drug development [10][23] - As of December 31, 2024, there were 3,575 active innovative drug projects in China, leading globally, with the number of first-in-class (FIC) drug pipelines increasing from 9 to 120 between 2015 and 2024, representing over 30% of the global total [10][23]

Core Insights - The Chinese innovative pharmaceutical industry is undergoing a historic transformation, shifting from "fast followers" to "originators" in drug development, supported by solid data and market performance [1] - By 2025, the total value of innovative drug licensing transactions in China is expected to exceed $130 billion, with over 150 transactions, marking a historical high [1] - Shanghai's Pudong district is becoming a key hub for the global market, with significant achievements in CAR-T products and first-class new drugs [1] Industry Performance - China's pharmaceutical industry ranks second globally, with approximately 30% of innovative drugs in development worldwide [1] - Pudong has approved 4 CAR-T products, accounting for 30% of the global total, and 7 first-class new drugs, representing 14% of the national total [1] - Business development (BD) transaction amounts in Pudong reached $20.4 billion, making up 14% of the global total [1] Competitive Advantages - Chinese innovative drug companies are gaining a competitive edge in the global market due to their speed and cost-effectiveness, being able to advance drug discovery 2-3 times faster and recruit clinical trial patients at half the cost compared to Western counterparts [2] - Companies like Maiwei Biotech and Jinsai Pharmaceutical are establishing significant overseas BD collaborations, enhancing China's global competitiveness in innovative drugs [2] Strategic Collaborations - Maiwei Biotech has accelerated its BD efforts, forming exclusive licensing agreements for innovative therapies, including a collaboration with Calico Life Sciences for an IL-11 targeted therapy [2][3] - Jinsai Pharmaceutical's subsidiary has signed an exclusive licensing agreement with Yarrow Bioscience for a monoclonal antibody, with potential milestone payments totaling up to $1.365 billion [4] Full-Chain Development - A number of innovative drug companies are building comprehensive overseas strategies that cover research, registration, and sales, transitioning from "licensing out" to "commercialization abroad" [5] - By 2024, Pudong is expected to have over 20 innovative drugs achieving commercial sales, with total sales exceeding 11.6 billion yuan [5] Global Market Positioning - Junshi Bioscience's innovative drug has become a benchmark for commercialization abroad, having been approved in over 40 countries and regions [5][6] - The core challenge for Chinese companies in international markets is to ensure their products meet local medical needs, requiring innovation, efficacy, and safety [5] Talent and Ecosystem - The rise of China's innovative drug industry is supported by years of policy guidance, technological accumulation, and capital cultivation, with a strong emphasis on the importance of a mature industrial ecosystem [12] - Pudong's unique industrial atmosphere, talent pool, and complete industrial chain are critical advantages for local companies [12][13] Future Outlook - The Pudong district plans to enhance its support for the life sciences industry, aiming to become a global hub for innovative drugs and medical devices by 2025 [15] - The industry anticipates that internationalization will remain a core development trend for domestic biopharmaceutical companies over the next 3-5 years [7][8]